What Is the Wasabi Compound (6-MSITC) and Does It Actually Improve Cognition and Healthy Aging? What the Evidence Shows

At a Glance: How 6-MSITC Compares to Other Cognitive Supplement Compounds

6-MSITC — formally defined as 6-methylsulfinyl hexyl isothiocyanate — is the principal bioactive compound isolated from the rhizome of Eutrema japonicum (wasabi). A 2023 double-blind randomized controlled trial published in Nutrients found that supplementing with it for 12 weeks significantly improved both working memory and episodic memory in healthy adults aged 60 and older. That single human trial, conducted by researchers at Tohoku University and affiliated institutions, is currently the most direct clinical evidence for a cognitive benefit in humans. It is worth understanding exactly what it showed, what it did not show, and what the broader body of preclinical science suggests about where this molecule might eventually matter most.

Before diving into the mechanistic detail, it helps to place 6-MSITC in context alongside other well-studied nootropic or neuroprotective compounds. The table below summarizes key data points across the evidence base.

Compound	Primary Source	Human RCT Evidence for Cognition	Key Mechanism(s)	Safety Profile (Human Data)
6-MSITC (hexaraphane)	Wasabi (Eutrema japonicum)	1 RCT (2023, n=72, adults ≥60); improved working + episodic memory	Nrf2/Keap1-ARE, MAPK, anti-inflammatory, antioxidant, dopaminergic neuroprotection	Demonstrated safe in rats and humans; open-label fatigue/sleep trials show tolerability
Bacopa monnieri	Ayurvedic herb	Multiple RCTs; mixed results; strongest for memory consolidation	Cholinergic modulation, antioxidant, BDNF upregulation	Generally well-tolerated; GI side effects at higher doses
Lion's Mane (Hericium erinaceus)	Medicinal mushroom	2–3 small RCTs; modest cognitive benefit in older adults	NGF stimulation, anti-neuroinflammatory	Well-tolerated in short-term studies
Phosphatidylserine	Soy/sunflower lecithin	Several RCTs; FDA-qualified health claim (with caveats)	Membrane fluidity, cholinergic signaling	Generally safe at 300–800 mg/day
Sulforaphane (from broccoli)	Brassica vegetables	Limited RCTs; preclinical data strong	Nrf2 activation, anti-inflammatory	Well-tolerated; bioavailability varies by source

6-MSITC is structurally related to sulforaphane — both are isothiocyanates from the Brassicaceae/Eutrema family — but differs in its six-carbon methylsulfinyl side chain, which influences both its potency on specific signaling pathways and its bioavailability characteristics. This structural distinction is part of why researchers at Poznan University of Medical Sciences describe 6-MSITC as a "promising candidate" for conditions ranging from Alzheimer's disease and Parkinson's disease to breast cancer, colorectal cancer, and obesity — though that language reflects the preclinical literature, not established clinical outcomes.

What Exactly Is 6-MSITC and Where Does It Come From?

6-MSITC is a naturally occurring isothiocyanate produced when the enzyme myrosinase acts on glucosinolate precursors in the wasabi rhizome — the same enzymatic reaction that generates the compound's characteristic sharp, pungent heat. When fresh wasabi is grated, cell walls rupture, myrosinase contacts its substrate, and 6-MSITC is released within seconds. This is why freshly grated wasabi differs substantially in bioactive content from the horseradish-based green paste served at most sushi restaurants outside Japan.

Kinjirushi, a Japanese company specializing in wasabi cultivation and processing, markets a standardized extract of this compound under the name "hexaraphane" and launched it in the U.S. market in October 2026. The branded ingredient is designed to deliver a consistent, measurable dose of 6-MSITC in supplement form — something that eating wasabi at a restaurant cannot reliably do, given the variability in preparation and the rarity of genuine Eutrema japonicum outside Japan.

"Wasabi has a long history in Japanese food culture, but our understanding of the plant keeps changing," said Isao Okunishi, Ph.D., fellow researcher at Kinjirushi, at the time of the U.S. launch. "Research into hexaraphane is helping us explore an entirely different side of wasabi."

What Did the 2023 Human RCT Actually Show?

The Tohoku University trial, led by Rui Nouchi and colleagues and published in Nutrients in November 2023, enrolled 72 healthy adults aged 60 and older in a double-blind, placebo-controlled, randomized design. Participants received either a wasabi supplement standardized to 6-MSITC or a matched placebo for 12 weeks. The primary outcomes were cognitive function measures across multiple domains.

The results showed statistically significant improvements in:

• Working memory — the ability to hold and manipulate information in real time, which is among the first cognitive capacities to decline with normal aging
• Episodic memory — the recall of specific past events and experiences, also highly age-sensitive

The trial did not find significant improvements across all cognitive domains tested. Processing speed, executive function, and attention did not show the same magnitude of benefit. This specificity is actually scientifically useful: it suggests the compound is not simply producing a global alertness effect (which would be more consistent with a stimulant mechanism) but may be acting on memory-specific neural circuits.

The trial has 10 Scopus citations as of 2026, a respectable early count for a niche ingredient study. Even so, it is a single trial with a relatively small sample size, and replication by independent research groups — ideally in larger and more diverse populations — has not yet occurred. Buyers and clinicians should weigh the result as promising but not yet definitive.

What Are the Proposed Mechanisms Behind 6-MSITC's Cognitive Effects?

The 2024 review published in Nutrients by Bartkowiak-Wieczorek and colleagues at Poznan University of Medical Sciences provides the most comprehensive mechanistic overview currently available. The authors identify several signaling pathways through which 6-MSITC exerts its biological effects.

Nrf2/Keap1-ARE pathway: This is the master regulator of the cellular antioxidant response. 6-MSITC activates Nrf2, which in turn upregulates a battery of endogenous antioxidant enzymes including heme oxygenase-1 (HO-1), glutathione S-transferase, and NAD(P)H quinone dehydrogenase 1 (NQO1). In the brain, oxidative stress is a key driver of neuronal damage in both normal aging and neurodegenerative disease, so Nrf2 activation is a plausible route to neuroprotection.

AMPK pathway: AMP-activated protein kinase is a central energy sensor in cells. 6-MSITC activates AMPK, which has downstream effects on metabolism, inflammation, and cellular autophagy — the process by which cells clear damaged proteins, including the amyloid-beta and tau aggregates implicated in Alzheimer's disease.

MAPK and ERK1/2 pathways: These kinase cascades regulate cell survival, differentiation, and inflammatory responses. 6-MSITC modulates these pathways in ways that appear to reduce neuroinflammation and support neuronal survival.

PI3K/AKT/mTOR pathway: This pathway governs cell growth and survival. In cancer contexts, 6-MSITC appears to suppress aberrant mTOR signaling; in neuronal contexts, appropriate mTOR modulation supports synaptic plasticity and memory consolidation.

Dopaminergic neuroprotection: Animal studies have shown that 6-MSITC protects dopaminergic neurons from oxidative damage — a finding particularly relevant to Parkinson's disease research, where the progressive loss of dopaminergic neurons in the substantia nigra drives motor and eventually cognitive decline.

The University of Bologna group's 2018 mouse study demonstrated that 6-MSITC reduced cognitive deficits, oxidative stress, inflammation, and apoptosis in a murine model of Alzheimer's disease induced by amyloid-beta (Aβ1-42) injection. This is one of the most mechanistically detailed preclinical demonstrations of the compound's neuroprotective potential, though the leap from an Aβ-injected mouse model to human Alzheimer's disease remains substantial.

Does 6-MSITC Have Benefits Beyond Cognition?

The preclinical evidence suggests yes. The human evidence outside the cognitive domain is thinner.

Chronic fatigue syndrome (ME/CFS): An open-label clinical trial evaluated wasabi extract containing 6-MSITC in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Participants reported improvements in fatigue symptoms, which aligns with the compound's anti-inflammatory and mitochondrial-supportive mechanisms. Open-label trials carry significant risk of placebo effect, so these results should be treated as hypothesis-generating rather than confirmatory.

Fatigue and sleep in healthy populations: A separate study linked 6-MSITC supplementation to improvements in fatigue and sleep quality in healthy adults, as referenced in the Kinjirushi launch coverage. Study design details matter here, and independent replication would strengthen confidence in these findings.

Cancer: The Bartkowiak-Wieczorek review summarizes in vitro and animal evidence showing 6-MSITC has anti-proliferative effects against breast cancer, colorectal cancer, and stomach cancer cell lines, operating through the ERK1/2-ELK1/CHOP/DR5 pathway to induce apoptosis in malignant cells. No human cancer trials exist for 6-MSITC specifically. This area of research is at an early exploratory stage.

Metabolic syndrome and obesity: AMPK activation by 6-MSITC has downstream effects on lipid metabolism and insulin sensitivity in animal models. The PPAR pathway — which regulates fat storage and glucose homeostasis — is also modulated by the compound. Human metabolic data are lacking, but the mechanistic rationale is coherent.

Cardiovascular health: Anti-inflammatory and antioxidant effects that reduce endothelial damage are proposed mechanisms for cardiovascular benefit, again primarily from preclinical data.

6-MSITC is a molecule with a genuinely broad mechanistic profile — the kind of pleiotropic activity that makes it scientifically interesting but also makes it harder to prioritize which clinical applications deserve the most rigorous investigation first.

How Does the Safety Profile Look?

Safety here means the absence of significant adverse effects at doses used in supplementation studies. Hexaraphane safety has been demonstrated in both rat and human studies, and the compound's profile across published trials is reassuring: no serious adverse events have been reported in the clinical literature to date.

This is consistent with the broader isothiocyanate class. Sulforaphane from broccoli, the most studied relative of 6-MSITC, has an extensive human safety record across dozens of trials. The structural similarity gives some confidence that 6-MSITC is unlikely to carry unexpected toxicity at supplemental doses, though the human exposure data for 6-MSITC specifically is far more limited than for sulforaphane.

The Bartkowiak-Wieczorek review notes that despite the "very promising results of in vitro and in vivo animal studies and a few human studies, the molecule has not yet been thoroughly tested in the human population." That is an accurate and appropriately cautious framing. Absence of reported harm in small trials is not the same as a fully characterized safety profile.

Who Is Kinjirushi and What Is Hexaraphane?

Kinjirushi is a Japanese company with deep roots in wasabi cultivation and processing. The company has developed a proprietary extraction and standardization process to produce hexaraphane — their branded name for a 6-MSITC-standardized wasabi extract — at a consistent potency suitable for dietary supplement formulation. The U.S. launch in October 2026 positions hexaraphane as a business-to-business ingredient for supplement brands to incorporate into finished products targeting cognitive health and healthy aging.

This is a meaningful distinction for consumers: hexaraphane is not yet a widely available consumer supplement brand in its own right. It is an ingredient that supplement manufacturers can license and formulate into their own products. Consumers looking for 6-MSITC-based supplements in 2026 should look for products that specifically list hexaraphane or 6-MSITC on the label and ideally disclose the dose used in the Tohoku University trial.

That dose has not been publicly disclosed in the abstract-level summaries available — a limitation for consumers trying to evaluate whether a given product delivers a clinically relevant amount. This is a common problem in the branded ingredient space and one worth asking supplement manufacturers about directly.

How Does 6-MSITC Fit Into the Broader Cognitive Supplement Space?

The cognitive supplement market is crowded with ingredients that have varying levels of human evidence. Phosphatidylserine carries an FDA-qualified health claim for cognitive decline, though the agency notes the evidence is limited and not conclusive. Bacopa monnieri has multiple RCTs but results are mixed across studies. Lion's mane mushroom has generated excitement, but the human trial base remains small.

6-MSITC sits in a similar position to lion's mane circa 2020: one reasonably well-designed human trial showing a specific memory benefit, a plausible multi-pathway mechanistic rationale, a good safety signal, and a need for more independent replication. That is a better evidentiary position than many ingredients on the market, but it is not the same as an ingredient with a decade of convergent human trial data.

For readers interested in related evidence-based supplement topics, the evidence on berberine for metabolic health and algae-derived omega-3 DHA for brain support represent adjacent areas where the human evidence base is more developed — useful context for anyone building a full cognitive health protocol.

What Should Consumers and Clinicians Take Away?

The evidence for 6-MSITC is best summarized this way: the compound is a bioactive isothiocyanate with genuine mechanistic plausibility for neuroprotection, and the single human RCT conducted to date supports a specific benefit for working and episodic memory in older adults. That is a meaningful result. It is also a result that needs replication.

For consumers aged 60 and older who are already interested in evidence-informed cognitive support strategies, 6-MSITC/hexaraphane is a reasonable ingredient to watch — and to try, given its favorable safety profile — while understanding that the evidence base is still early. It is not a substitute for the lifestyle factors (aerobic exercise, sleep quality, dietary pattern, social engagement) that have far more solid evidence for cognitive aging outcomes.

Clinicians will find the mechanistic overlap with Alzheimer's disease pathology worth tracking: Nrf2 activation, AMPK-driven autophagy, amyloid-beta protection in animal models — the rationale is scientifically coherent. If larger trials confirm the memory findings, 6-MSITC could become a meaningful adjunct in cognitive aging protocols.

For supplement brands, hexaraphane's U.S. launch represents an opportunity to differentiate in a crowded nootropic market with an ingredient that has a genuine peer-reviewed trial behind it, a compelling origin story in Japanese food culture, and a mechanistic profile that supports multiple health claims — provided those claims are made carefully and within regulatory bounds.

The wasabi plant has been a fixture of Japanese cuisine for centuries. What the science is now beginning to reveal is that its most interesting properties may have less to do with the sinus-clearing heat at the sushi counter and more to do with what its primary bioactive compound does inside aging neurons.